CanSino looks for next growth shot in ‘life after Covid’
The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
Riding Covid Vaccine Highs, CanSino Plans Swiss Listing
The first vaccine stock to be listed in the both Mainland China and Hong Kong will issue global depositary receipts (GDRs) in SwitzerlandKey Takeaways:After successful listings in Shanghai and Hong…
Clover Biopharma Gets Critical Cash Booster After Covid Vaccine Approval
The innovative drug maker announced a major share sale a day after its self-developed Covid-19 vaccine got the green light for emergency use in ChinaKey Takeaways:Clover Biopharmaceuticals raised $64 million…
CanSino’s Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late?
The company’s Convidecia has received emergency-use authorization from the World Health Organization, becoming the third Chinese vaccine to get that nod Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted…
